Nov. 18, 2008-The European Medicines Agency (EMEA) has been formally notified by Novagali Pharma S.A. of its decision to withdraw its application for a centralised marketing authorisation for the medicine Vekacia (ciclosporin) 0.05% eye drops. Vekacia was expected to be used for the treatment of vernal keratoconjunctivitis. Vekacia was designated as an orphan medicine on 6 April 2006.
The details can be read here.
No comments:
Post a Comment